Royalty Pharma plc
Royalty Pharma plc is a U.S.-listed biopharmaceutical royalty company organized through a holding-company structure in England and Wales. It acquires and holds royalty interests and other interests tied to the sales of approved medicines and development-stage therapies, generating returns from the top-line performance of those products across global markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRoyalties tied to sales of marketed biopharmaceutical products.
Interests linked to product candidates that may generate future royalties.
Royalty-like interests created by biotech companies on existing therapies.
Additional royalty receivables, intangible interests, and related assets.
Products
Reported · share of revenue- Financial Royalty Assets95.1 %
- Royalty Income Other4.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Royalty Pharma's counterparties are biopharmaceutical innovators rather than end patients: academic institutions, research hospitals, not-for-profits, biotechnology companies, and large pharmaceutical companies that monetize future product sales. It also depends on the marketers and payors of the underlying drugs, since royalty receipts are driven by the commercial success of those therapies.
They sell royalty interests or synthetic royalties to raise non-dilutive capital while retaining operational control of programs.
They market approved therapies that generate royalty payments on commercial sales.
They monetize intellectual property from discoveries and early-stage programs.
They license or sell royalty rights tied to therapeutic innovations.
They do not buy from the company, but their pricing and reimbursement decisions determine royalty-bearing sales.
Strategy
Royalty Pharma focuses on selectively acquiring royalty streams on important therapies and product candidates, using its scale and specialist underwriting to source transactions. It also emphasizes capital allocation discipline, portfolio diversification across products and stages, and participation in the growing market for synthetic royalties.
A broader portfolio reduces dependence on any single product and increases exposure to multiple therapeutic franchises.
Royalties on therapies addressing unmet needs are more likely to sustain commercialization and pricing power.
Synthetic royalties are an expanding source of deal flow as biotech companies seek non-dilutive capital.
Returns depend on buying royalty streams at attractive prices relative to expected future cash flows.
Geography
Royalty Pharma is incorporated in England and Wales, but its business is global because the underlying therapies are sold in major pharmaceutical markets worldwide. The company specifically highlights exposure to the U.S., EU, UK, Japan, and China through the pricing and reimbursement systems that affect royalty-generating products.
Risks
The business depends on the commercial success of third-party biopharmaceutical products, so patent loss, generic or biosimilar competition, pricing pressure, and regulatory exclusivity changes can reduce royalty income. It also faces structural and financial risks from leverage, foreign exchange, interest rates, and the holding-company model, while accounting outcomes depend heavily on estimates of future royalty cash flows.
- Sales risk on royalty-bearing productsImpact: HighLikelihood: Medium
Royalty receipts depend on third-party products remaining commercially successful.
Exposure: Commercial therapies in the portfolio
- Patent, exclusivity, and competition riskImpact: HighLikelihood: Medium
Generics, biosimilars, or loss of exclusivity can reduce or eliminate royalty streams.
Exposure: Products with finite exclusivity periods
- Pricing and reimbursement pressureImpact: HighLikelihood: Medium
Drug pricing scrutiny and payer decisions can limit sales growth and royalty value.
Exposure - Interest rate, FX, and leverage riskImpact: MediumLikelihood: High
Capital deployment and financing costs can affect returns and reported results.
Exposure: Debt-funded investments and global cash flows
- Royalty market and acquisition riskImpact: MediumLikelihood: Medium
Future returns depend on sourcing attractive royalty assets in a competitive market.
Exposure: New royalty acquisitions and development-stage deals
- Holding-company and organizational structure riskImpact: MediumLikelihood: Low
Cash generation and obligations flow through subsidiaries and related entities.
Exposure: Corporate structure and internalization-related arrangements
Accounting
Judgemental itemsCarrying values and interest income depend on forecasts of future royalty receipts.
Impact: Can materially affect revenue recognition and asset balances
Interest income is recognized based on updated expected cash flows from royalty assets.
Impact: Affects timing and amount of reported income
Weaker product sales or loss of exclusivity can require write-downs.
Impact: Can reduce earnings and asset values
Different royalty structures are accounted for differently depending on rights acquired.
Impact: Changes presentation, amortization, and measurement
Similar listed companies
Publicly listed companies with a comparable business focus.
XOMA Royalty Corp
Pharmaceutical Preparations
XOMA Royalty Corp is a U.S.-based biotech royalty aggregator that acquires economic rights to future milestone payments, royalties, and commercial payments from partnered therapeutic programs.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Xencor Inc
XNCR · Pharmaceutical Preparations
Last updated: 24/09/2026